Publications by authors named "M Bunker"

Background: Few treatments are available for individuals with marked treatment-resistant depression (TRD).

Objective: Evaluate the safety and effectiveness of FDA-approved adjunctive vagus nerve stimulation (VNS) in patients with marked TRD.

Methods: This 12-month, multicenter, double-blind, sham-controlled trial included 493 adults with marked treatment-resistant major depression who were randomized to active or no-stimulation sham VNS for 12 months.

View Article and Find Full Text PDF

Background: Depression treatments aim to minimize symptom burden and optimize quality of life (QoL) and psychosocial function.

Objective: Compare the effects of adjunctive versus sham vagus nerve stimulation (VNS) on QoL and function in markedly treatment-resistant depression (TRD).

Methods: In this multicenter, double-blind, sham-controlled trial, 493 adults with TRD and ≥4 adequate but unsuccessful antidepressant treatment trials (current episode) were randomized to active (n = 249) or sham (n = 244) VNS (plus treatment as usual) over a 12-month observation period.

View Article and Find Full Text PDF
Article Synopsis
  • Systemic Epstein-Barr virus-positive T-cell lymphoma (TCL) in children is rare and often follows an EBV infection, leading to a hyperinflammatory state and poor outcomes, often presenting with hemophagocytic lymphohistiocytosis (HLH) syndrome.
  • The disorder involves a hyperactive immune response and may be linked to genetic alterations on chromosome 22q11.2, increasing the risk of non-Hodgkin lymphoma later in life.
  • A case study of a 21-year-old male who developed HLH from an EBV infection ultimately resulted in a diagnosis of systemic EBV TCL, and despite treatment, he did not survive before receiving a stem cell transplant, highlighting the need for awareness
View Article and Find Full Text PDF

All definitions of treatment-resistant depression (TRD) require that patients have experienced insufficient benefit from one or more adequate antidepressant trials. Thus, identifying "failed, adequate trials" is key to the assessment of TRD. The Antidepressant Treatment History Form (ATHF) was one of the first and most widely used instruments that provided objective criteria in making these assessments.

View Article and Find Full Text PDF